You are here

Special Investigation Of Genotropin Long Follow-Up For Patients With A Small For Gestational Age (SGA)

Last updated on May 11, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Small for Gestational Age (SGA)
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0-20
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- A patient who was administered Somatropin (Genotropin).

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
NCT01897766
Pfizer
Completed
Special Investigation Of Genotropin Long Follow-Up For Patients With A Small For Gestational Age (SGA)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Pancreatic Cancer, Non-Small Cell Lung Cancer, Cancer
NCT03637491
All Genders
18+
Years
Houston, Texas
Non-Small-Cell Lung Carcinoma
NCT03052608
All Genders
18+
Years
Multiple Sites
Special Investigation Of Genotropin Long Follow-Up For Patients With A Small For Gestational Age (SGA)
Special Investigation For Genotropin(Sga Long Follow-up)
The objective of this surveillance is to collect Safety and Effectiveness information for Long term Use of Somatropin for Patients with a Small for Gestational Age (SGA).
All the patients whom an investigator prescribes Genotropin should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample
  • A patients who is diagnosed for SGA. (SGA is defined as birth weight and/or length at least 2 standard deviations (SDs) below the mean for gestational age (
  • A patient who is SGA and older than 3 years.
  • A patient who has persistent short stature (i.e., remaining at least 2.5 SD below the mean for chronologic age).
Small for Gestational Age (SGA)
Drug: Somatropin
0.23 mg to 0.48 mg/kg/week
Somatropin
Patients administered Somatropin.
Intervention: Drug: Somatropin
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
488
February 2017
February 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • A patient who was administered Somatropin (Genotropin).

Exclusion Criteria:

Sexes Eligible for Study: All
up to 20 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01897766
A6281314
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
April 2017

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now